Nov 7 Statement | UMR Congratulates Dr. Monica Bertagnolli on her Confirmation as the next NIH Director
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
2023 Rural State Analysis | UMR's Newest Report Reveals the Exponential Impact of NIH Research Funding in Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

New clinical trial means real data in COVID-19 fight, maybe answers

In continued combat against COVID-19, the call for more and better data has grown gradually louder: good information to help equip researchers with understanding of the virus — and options to fight it. One of the treatments now considered among the more promising: convalescent plasma — shown as safe over decades of use, and widely touted for its promise. Yet it must face further clinical trial.

Now, Vanderbilt University Medical Center has received a $34 million grant to conduct a yearlong, nationwide study of convalescent plasma to treat COVID-19. The study will furnish what health officials have been urging: robust data built on randomized, controlled experiments which could help fill the knowledge gaps about the virus.